Efficacy of an alginate versus proton pump inhibitor in the symptomatic relief of gastroesophageal reflux symptoms in pregnant women

Jayanthy T.; Vayyala P. Reddy

doi:10.18203/2320-1770.ijrcog20231524

Authors

Jayanthy T. Department of Obstetrics and Gynecology, Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India
Vayyala P. Reddy Department of Obstetrics and Gynecology, Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20231524

Keywords:

Alginates, Pantoprazole, GERD, Heartburn

Abstract

Background: Gastroesophageal reflux disease (GERD) is frequently seen during pregnancy with prevalence of 80%. Proton pump inhibitors (PPI) are the most effective drugs used in the treatment of reflux symptoms. Alginates are natural polysaccharide polymer which builds a non-systemic barrier against acid and food reflux in the oesophagus. Aims and objectives were to compare the efficacy of alginate versus PPIs in pregnant women, and to determine the time to onset of decrease in the pain intensity of alginate to PPIs.

Methods: This is a prospective randomised study conducted in pregnant women with symptoms of heartburn comparing the efficacy of alginates to PPIs in Kempegowda Institute of Medical Sciences. After subjects have signed the consent, two sachets of 10 ml liquid preparation alginate were given to the alginate group while 40 mg intravenous pantoprazole to the PPI group.

Results: Among 40 patients studied, 20 were given alginates and 20 were given PPIs. 7 presented in the 1st trimester and 33 in 2nd trimester. Onset of action is faster with alginates when compared to PPIs, it was 30 min to 1 hour in patients taking alginates and 6-12 hours in patients taking PPIs, duration of action was longer for PPIs than alginates, with alginates it’s observed that it attains 24-hour symptom free interval in shorter time when compared to PPIs.

Conclusions: ¬Alginates to be used for rapid symptom relief in patients with acute symptoms as an induction agent, PPIs to be used for longer duration of action as maintenance.

Metrics

Metrics Loading ...

References

Malfertheiner SF, Malfertheiner MV, Mönkemüller K, Röhl FW, Mal- fertheiner P, Costa SD. Gastroesophageal reflux disease and man- agement in advanced pregnancy: a prospective survey. Digestion. 2009;79(2):115-20.

Ramu B, Mohan P, Rajasekaran MS, Jayanthi V. Prevalence and risk factors for gastroesophageal reflux in pregnancy. Indian J Gastroenterol. 2011;30(3):144-7.

Bassey OO. Pregnancy heartburn in Nigerians and Caucasians with theories about aetiology based on manometric recordings from the oesophagus and stomach. BJOG. 1977;84(6):439-43.

Malfertheiner SF, Malfertheiner MV, Kropf S, Costa SD, Malfertheiner P. A prospective longitudinal cohort study: evolution of GERD symptoms during the course of pregnancy. BMC Gastroenterol. 2012;12(1):131.

Malfertheiner M, Malfertheiner P, Costa SD, Pfeifer M, Ernst W, Seelbach- Göbel B, et al. Extraesophageal symptoms of gastroesophageal reflux disease during pregnancy. Z Gastroenterol. 2015;53(09):1080-3.

National Collaborating Centre for Women ’s and Children ’s Health. Antenatal care routine care for the healthy pregnant woman. Available at: https://www.nice.org.uk/guidance/cg62/evidence/full-guideline-pdf-196748323. Accessed on 24 April 2023.

Phupong V, Hanprasertpong T. Interventions for heartburn in pregnancy. Cochrane Database Syst Rev. 2015;9:CD011379.

Van Der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. Gut. 2014;63(6):1014-23.

Gomes CF, Sousa M, Lourenço I, Martins D, Torres J. Gastrointestinal diseases during pregnancy: what does the gastroenterologist need to know? Ann Gastroenterol. 2018;31(4):385-94.

Body C, Christie JA. Gastrointestinal diseases in pregnancy: nausea, vomiting, hyperemesis gravidarum, gastroesophageal reflux disease, constipation, and diarrhea. Gastroenterol Clin N Am. 2016;45(2):267-83.

Clark SM, Dutta E, Hankins GD. The outpatient management and special considerations of nausea and vomiting in pregnancy. Semin Perinatol. 2014;38(8):496-502.

Zielinski R, Searing K, Deibel M. Gastrointestinal distress in pregnancy. J Perinat Neonatal Nurs. 2015;29(1):23-31.

Marrero JM, Goggin PM, de Caestecker JS, Pearce JM, Maxwell JD. Determinants of pregnancy heartburn. Br J Obstet Gynaecol. 1992;99:731-4.

Van Thiel DH, Gavaler JS, Joshi SN, Sara RK, Stremple J. Heartburn of pregnancy. Gastroenterology. 1977;72:666-8.

Rohof WO, Bennink RJ, Smout AJ, Thomas E, Boeckxstaens GE. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease. Clin Gas- troenterol Hepatol. 2013;11(12):1585-91.

Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial. BMC Gastroenterol. 2012;12:18.

Uzan M, Uzan S, Sureau C, Richard-Berthe C. Pyrosis and regurgitations during pregnancy. Efficacy and innocuous- ness of a treatment with Gaviscon suspension. Revue Fran- caise de Gynecologie et d’Obstetrique. 1988;83(7-9):569-72.

Lindow SW, Regnéll P, Sykes J, Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int J Clin Pract. 2003;57(3):175-9.

Hutt HJ, Tauber O, Flach D. Gavisconinthetreatment of reflux disease. Results of an observational study. Fortschrit- te der Medizin. 1990;108:598-600.

Lindow SW, Regnéll P, Sykes J, Little S. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (gaviscon advance) in the treatment of heartburn during pregnancy. Int J Clin Pract. 2003;57(3):175-9.

De Bellis I, Epifani S, Maiorino R, Tardio R. Gastroe- sophageal reflux in pregnancy. Giornale Italianodi Ostetricia e Ginecologia. 1999;21(1):17-9.